Effect of sorafenib combined with transarterial chemoembolization and percutaneous local cryotherapy on treating advanced hepatocellular carcinoma
10.3760/cma.j.issn.1008-6315.2014.07.024
- VernacularTitle:索拉菲尼联合肝动脉栓塞化疗和氩氦刀消融治疗晚期肝癌的效果观察
- Author:
Rui FENG
;
Fang LIU
;
Yifeng BAI
- Publication Type:Journal Article
- Keywords:
Sorafenib;
Transarterial chemoembolization;
Argon helium cryoablation;
Liver cancer
- From:
Clinical Medicine of China
2014;(7):739-742
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of sorafenib alone or combination with transarterial chemoembolization(TACE)and percutaneous local cryotherapy(PLCT)for advanced hepatocellular carcinoma patients without operation opportunity. Methods Sixty-four advanced hepatocellular carcinoma patients were selected as our subjects,who were underwent treatment of sorafenib alone or combination with TACE and PLCT. Thirty-two cases with sorafenib therapy were served as sorafenib group and another 32 cases with sorafenib in combination with transarterial chemoembolization and PLCT were served as combination group. All patients were followed up for 6 - 32 months. The treatment efficacy and tumor development were recorded. Results All surgeries of the patients were succeed and no death or serious operation complications occurred. Of 64 patients, 11 were achieved a complete remission( CR),31 cases with partial remission( PR),14 cases with stable development(SD),and 8 cases with progressive disease(PD). In the sorafenib group,3 cases were with CR,11 patients with PR,12 with SD,and 6 patients with PD. In the combination group,8 patients were with CR,20 patients with PR,2 patients with SD and 2 patients with PD,and the difference was significant between the two groups(χ2 = 14. 028,P = 0. 003). The median periods to tumor progression were 20 and 53 weeks in the sorafenib group and the combination group,and the difference was significant( χ2 = 14. 773,P = 0. 000). Conclusion For hepatocellular carcinoma patients without operation opportunity,sorafenib combined with TACE and PLCT can increase the tumor remission rate and prolong the periods to tumor progression in patients with hepatocellular carcinoma.
